Philadelphia, PA – According to filings with the U.S. Securities and Exchange Commission, NephroDI Therapeutics is raising $1,600,018.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Rachael Hagan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About NephroDI Therapeutics

NephroDI Therapeutics is a pharmaceutical company that focuses on concentration disorders of the kidney. The initial clinical indication for its orally administered lead small molecule is for Nephrogenic Diabetes Insipidus in children, a pediatric orphan indication. Currently there is no effective therapy for NDI. Current management requires patients to drink as much fluid as they excrete to prevent dehydration. There is a compelling clinical need for an effective therapy. A therapy that significantly reduces urine output would be a tremendous benefit to children suffering from NDI.

To learn more about NephroDI Therapeutics, visit http://nephrodi.com/

Contact:
Rachael Hagan, President and Chief Executive Officer
206-696-0546
rhagan@nephrodi.com
https://www.linkedin.com/in/rahagan/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved